ArticleBlood advances2018

The SMAC mimetic LCL-161 displays antitumor activity in preclinical models of rituximab-resistant B-cell lymphoma.

Kyle Runckel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.